Reference

1. Streubel A, Siepmann J, Bodmeier R. Gastroretentive drug delivery system. Expert Opin Drug Deliv 2006; 3(2): 217- 33. 
2. Iannucelli V, Coppi G, Bernabei MT, Camerorni R. Air compertment multiple-unit system for prolonged gastric residence. Part-I. Formulation study. Int J Pharm 1998; 174: 47-54. 
3. Garg R, Gupta GD. Progress in controlled gastroretentive delivery systems. Trop. J Pharm Res 2008; 7(3): 1055-66. 
4. Rouge N, Allemann E, Gex-Fabry M, Balant L, Cole ET, Buri P, Doelker E. Comparative pharmacokinetic study of a floating multiple-unit capsule, a high density multipleunit capsule and an immediate-release tablet containing 25 mg atenolol. Pharm Acta Helbetiae 1998; 73: 81-7. 
5. Streubel A, Siepmann J, Bodmeier R. Multiple unit Gastroretentive drug delivery: a new preparation method for low density microparticles. J Microencapsul 2003; 20: 329-47. 
6. Goole J, Vanderbist F, Aruighi K. Development and evaluation of new multiple-unit levodopa sustained-release floating dosage forms. Int J Pharm 2007; 334: 35-41.
7. Shrma S, Pawar A. Low density multiparticulate system for pulsatile release of meloxicam. Int J Pharm 2006; 313: 150-58. 
8. Santus G, Lazzarini G, Bottoni G, Sandefer EP, Page RC, Doll WJ, Ryo UY, Digenis GA. An in vitro- in vivo investigation of oral bioadhesive controlled release furosemide formulations. Eur J Pharm Biopharm 1997; 44: 39-52. 
9. Klausner EA, Lavy E, Friedman M, Hoffman A. Expandable gastroretentive dosage forms. J Control Release 2003; 90: 143-62. 
10. Deshpande AA, Shah N, Rhodes CT, Malik W. Development of a novel controlled-release system for gastric retention. Pharm Res 1997; 14: 815-19. 
11. Park K. Enzyme-digestible swelling as platforms for longterm oral drug delivery: synthesis and characterization. Biomaterials 1988; 9: 435. 
12. Fujimori J, Machida Y, Nagai T. Preparation of a magnetically-responsive tablet and configuration of its gastric residence in beagle dogs. STP Pharma Sci 1994; 4: 425-30. 
13. Wilson CG, Washington N. The stomach: its role in oral drug delivery. In: Rubinstein, MH, editors. Physiological Pharmaceutical: Biological barriers to drug absorption. Chichester, U.K.: Ellis Horwood. 1989. p. 47-70. 
14. Streubel A, Siepmann J, Bodmeier R. Drug delivery to the upper small intestine window using Gastroretentive technologies. Curr Opin Pharmacol 2006; 6: 501-8. 
15. Larhed AW, Artursson P, Grasjo J, Bjork K. Diffusion of drugs in native and purified gastrointestinal mucus. J Pharm Sci 1997; 86(6): 660-65. 
16. Dubernet C. Syste`mes a` liberation gastrique prolonge`e. In: Falson-Rieg F, Faivre V, Pirot F, editors. Novelles formes me`dicamenteuses. Editions Me`dicales Internationales. Editions TEC and DOC. Cachan. 2004. p. 119-33.
17. .Arrora S, Ali J, Khar RK, Baboota S. Floatng drug delivery systems: A review. AAPS Pharm Sci Tech 2005; 6(3): 372-90. 
18. El-Kamel AH, Sokar MS, Al Gamal SS, Naggar VF. Preparation and evaluation of ketoprofen floating oral delivery system. Int J Parm 2001; 220: 13-21. 
19. Garg S, Sharma S. Gastroretentive drug delivery systems. Business Briefing: Pharmatech 2003: 160-66. 
20. Khosla R, Feely LC, Davis SS. Gastrointestinal transit of non-disintegrating tablets in fed subjects. Int J Pharm 1989; 53: 107-17. 
21. Mojaverian P, Vlasses PH, Kellner PE, Rocci Jr ML. Effects of gender, posture and age on gastric residence time of an indigestible solid: Pharmaceutical considerations. Pharm Res 1988; 10: 639-44. 
22. .Vyas SP, Khar RK. Gastroretentive systems. In: Controlled drug Delivery. Vallabh Prakashan, Delhi, India. 2006. p. 197-217.
23. Clarke GM, Newton JM, Short MD. Gastrointestinal transit of pellets of differing size and density. Int J Pharm 1993; 100(13): 81-92.
24. Moes AJ. Gastric retention systems for oral drug delivery. Business Briefing: Pharmatech 2003: 157-59.
25. Sing BN, Kim KH. Floating drug delivery systems: an approach to oral controlled drug delivery via gastric retention. J Control Rel 2000; 63: 235-59.
26. Sungthongjeen S, Paeratakul O, Limmatvapirat S, Puttipupathachorn S. Preparation and in-vitro evaluation of multiple-unit floating drug delivery system based on gas formation technique. Int J Pharm 2006; 324: 136-43.
27. Krogel I, Bodmeier R. Development of a multifunctional matrix drug delivery system surrounded by an impermeable cylinder. J Control release 1999; 61: 43-50.
28. Sriamornsak P, Thirawong N, Puttipipatkhachorn S. Emulsion gel beads of calcium pectinate capable of floating on the gastric fluid: effect of some additives, hardening agent or coating on release behavior of metronidazole. Eur J Pharm Sci 2005; 24: 363-73.
29. Streubel A, Siepmann J, Bodmeier R. Floating microparticles based on low density foam powder. Int J Pharm 2002; 241: 279-92.
30. Streubel A, Siepmann J, Bodmeier R. Floating matrix tablets based on low density foam powder: effects of formulation and processing parameters on drug release. Eur J Pharm Sci 2003; 18: 37-45.
31. Sato Y, Kawashima Y, Takenchi H, Yamamoto H. Physicochemical properties to determine the buoyancy of hollow microspheres (microballoons) prepared by the emulsion solvent diffusion method. Eur J Pharm Biopharm 2003; 55: 297-304. 
32. Talukdar R, Fassihi R. Gastroretentive delivery systems: hollow beads. Drug Dev Ind Pharm 2004; 30: 405-12.
33. Hilton AK, Deasy PB. In vitro and in vivo evaluation of an oral sustained release floating dosage form of amoxicillin trihydrate. Int J Pharm 1992; 86: 79-88.
34. Seth PR, Tossounian J. The hydrodynamically balanced system, a novel drug delivery system for oral use. Drug Dev Ind Pharm 1984; 10: 313-39.
35. Hwang SJ, Park H, Park K. Gastroretentive delivery systems. Crit Rev Ther Drug Carrier Syst 1998; 15(3): 243-84.
36. Reddy LH, Murthy RS. Floating dosage system in drug delivery. Crit Rev Ther Drug Carrier Syst 2002; 19(6): 553-85.
37. Bardonnet PL, Faivre V, Pugh WJ, Piffaretti JC, Falson F. Gastroretentive dosage forms: overview and special case of Helicibacter pylori. J Control Release 2006; 111: 1-18.
38. Kawashima Y, Niwa T, Takenchi H, Hino T, Itoh Y. Hollow microspheres for use as a floating controlled drug delivery system in the stomach. J Pharm Sci 1992; 81: 135- 40.
39. Whiteland L, Fell JT, Collett JH. Development of gastroretentive dosage form. Eur J Pharm Sci 1996; 4(suppl.): S182. 
40. Harrigan RM. Drug delivery device for preventing contact of undissolved drug with the stomach lining. US Patent 405 5178; October 25, 1977. 
41. Ingani HM, Timmermans J, Moes A. Conception and in vivo investigation of per oral sustained release floating dosage forms with enhanced gastrointestinal transit. Int J Pharm 1987; 35(12): 157-64.
42. Krogel I, Bodmeir R. Floating or pulsatile drug delivery system based on coated effervescent cores. Int J Pharm 1999; 187(2): 175-84.
43. Moes A. Gastroretentive dosage forms. Crit Rev Ther Drug Carrier Syst 1993; 10: 143-95.
44. Faivre V. Aspects theoriques de la bioadhesion. In: FalsonRieg V, Faivre V, Pirot F. ed. Nonvelles formes medicamenteuses , Editions Medicales Internationales, Editions TEC and DOC, Cachan. 2004. p. 1-24.
45. .Huang Y, Leobandung W, Foss A, Peppas NA. Molecular aspects of muco- and bioadhesion: tethered structures and site-specific surfaces. J Control Release 2000; 65(1-2): 63- 71. 
46. Klusner EA, Lavy E, Friedman M, Hoffman A. Expandable gasrtroretentive dosage forms. J Control Release 2003; 90(2): 143-62.
47. Klusner EA, Lavy E, Stepensley D, Friedman M, Hoffman A. Novel gasrtroretentive dosage form: evaluation of gastroretentivity and its effect on riboflavin absorption in dogs. Pharm Res 2002; 19: 1516-23.
48. Caldwell LJ, Gardner CR, Cargill RC. Drug delivery device which can be retained in the stomach for controlled period of time. US Patent 473 5804. April 5, 1988.
49. Caldwell LJ, Gardner CR, Cargill RC, Higuchi T. Drug delivery device which can be retained in the stomach for a controlled period of time. US Patent 475 8436: July 19, 1988.
50. Klusner EA, Lavy E, Barta M, Cserepes E, Friedman M, Hoffman A. Novel gasrtroretentive dosage form: evaluation of gastroretentivity and its effect on levodopa absorption in humans. Pharm Res 2003; 20(9): 1466-73.
51. Chen J, Blevins WE, Park H, Park K. Gastric retention of superporous hydrogel composites. J Control Release 2000; 64(1-3): 39-51
52. Chen J, Park K. Synthesis and characterization of superporous hydrogel composites. J Control Release 2000; 65(1-2): 73-82.
53. Chawla G, Gupta P, Bansal AK. Gastroretentive drug delivery systems. In: Jain NK. editor. Progress in controlled and novel drug delivery systems. CBS Publishers and Distributors. New Delhi. 2004. p. 76-97.
54. Klusner EA, Eyal S, Lavy E, Friedman M, Hoffman A. Novel levodopa gasrtroretentive dosage form: in vivo evaluation in dogs. J Control Release 2003; 88: 117-26.
55. Hoffman A. Pharmacodynamic aspects of sustained release preparation. Adv Drug Deliv Rev 1998; 33: 185-99